CRISPR Therapeutics reported strong Q4 2025 results with Casgevy gene therapy generating $116 million in annual revenue and 147 patient initiations, nearly tripling from 2024. The company is advancing its pipeline with in vivo liver editing programs and RNA-based candidates. Shares surged 8.81% on the positive clinical progress and expanding market access.

The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.

Arrowhead Pharmaceuticals reported positive interim Phase 1/2a trial results for its obesity drugs ARO-INHBE and ARO-ALK7, which use RNA interference to target fat storage pathways. ARO-INHBE doubled weight loss and tripled fat reductions when combined with Eli Lilly's tirzepatide, while ARO-ALK7 showed rapid visceral fat reductions. Both candidates were well-tolerated, and the stock surged 17.81% to a new 52-week high.

The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.

The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Zoom Video Communications The Trade: Zoom Video Communications, Inc. (NASDAQ: ZM) Director Santiago Subotovsky sold a total of 1,100 shares at an average price of $65.38. The insider received around $71,919 from selling those shares. What’s Happening: On March 26, Rosenblatt analyst Catharine Trebnick reiterated ...

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. Shares of EQT Corporation (NYSE: EQT) fell sharply during Monday’s session after the company announced that it entered into a definitive merger agreement to acquire Equitrans Midstream. EQT shares fell 8.4% to $34.37 on Monday. Here are some other big stocks recording losses in today’s session. Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares tumbled 18.5% to $8.09. Ventyx Biosciences reported clinical data for its NLRP3 inhibitor portfolio and issued pipeline updates at Virtual Investor Event. MoneyLion Inc. (NYSE: ML) dipped 15% to $63.36. Genie Energy Ltd. ...

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The Cooper Companies, Inc. (NYSE: COO) rose sharply during Friday’s session after the company reported better-than-expected first-quarter financial results and raised guidance. Cooper Companies posted adjusted earnings of 85 cents per share, beating market estimates of 78 cents per share. The company’s quarterly sales came in at $931.60 million versus expectations of $915.94 million, according to data from Benzinga Pro. The Cooper Companies shares rose 7.4% to $100.61 on Friday. Here are some other big stocks recording gains in today’s session. Dell Technologies Inc. (NYSE: DELL) jumped 26.3% to $119.52 as the company reported better-than-expected fourth-quarter financial results and increased its annual cash dividend by 20%. Sweetgreen, Inc. (NYSE: SG) rose 26% to $16.05 after the company reported better-than-expected fourth-quarter financial results. Everbridge, Inc. (NASDAQ: EVBG) climbed 24.5% to $35.19 after it amended and restated the previously announced merger agreement with Thoma Bravo. NetApp, Inc. (NASDAQ:

Analysts' ratings for Arrowhead Pharma (NASDAQ:ARWR) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 1 1 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $42.17, a high estimate of $50.00, and a low estimate of $29.00. Surpassing the previous average price target of $34.50, the current average has increased by 22.23%. Interpreting Analyst Ratings: A Closer Look An in-depth analysis of recent analyst actions unveils how financial experts perceive Arrowhead Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Luca Issi RBC Capital Maintains Outperform $50.00 - Luca Issi RBC Capital Maintains Outperform $50.00 - Jason Gerberry B of A Securities Raises Buy $37.00 $29.00 Jason Gerberry B of A Securities Announces Buy $29.00 - Michael Ulz Morgan Stanley Lowers Equal-Weight $37.00 $40.00 Luca Issi RBC Capital Maintains Outperform $50.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ...Full story available on Benzinga.com

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following better-than-expected quarterly results. Lamb Weston posted adjusted earnings of $1.45 per share, beating market estimates of $1.41 per share. The company’s quarterly sales came in at $1.73 billion versus estimates of $1.70 billion. Lamb Weston shares gained 4.7% to $109.86 on Thursday. Here are some other big stocks recording gains in today’s session. Omega Therapeutics, Inc. (NASDAQ: OMGA) gained 92.7% to $5.26 after Novo Nordisk entered into a research collaboration with the company. QuantumScape Corporation (NYSE: QS) jumped 18.5% to $7.70. Keros Therapeutics, Inc. (NASDAQ: KROS) rose 15.7% to $47.72. Keros Therapeutics priced upsized $140 million public offering of ...

Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock. Keefe, Bruyette & Woods analyst Michael Perito downgraded SoFi from a Market Perform rating to an Underperform rating and lowered the price target from $7.50 to $6.50, citing recent outperformance and a change in the analyst's model. SoFi Technologies shares dipped 12.8% to $8.41 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers NexImmune, Inc. (NASDAQ: NEXI) shares rose 150.8% to $6.14 after gaining over 6% on Tuesday. Trinity Place Holdings Inc. (NYSE: TPHS) rose gained 62.6% to $0.1857. The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan. 31, 2024. Sigma Additive Solutions, Inc.(NASDAQ: SASI) gained 60.3% to $4.65. Sigma Additive Solutions, announced in an 8-K Filing, the approval of the issuance of the shares of common stock in exchange for all the capital stock of NextTrip Holdings. ABVC BioPharma, Inc. (NASDAQ: ABVC) jumped 58.3% to $1.90. ABVC BioPharma and its subsidiary received $460 million from AiBtl BioPharma as the first milestone payment of global licensing fees. Sidus Space, Inc. (NASDAQ: SIDU) rose 48.4% to $10.35. Sidus Space secured NOAA approval to provide imaging services to government and commercial customers. Brera Holdings PLC (NASDAQ: BREA) shares gained 32.8% to $0.97. First Wave BioPharma, Inc. (NASDAQ: FWBI) shares gained 31.2% to $5.01. Roth MKM raised price target on the stock to $40. Elicio Therapeutics, Inc. (NASDAQ: ELTX) gained 29% to $7.65. TDCX Inc. (NYSE: TDCX) gained 28% to $6.18 after it disclosed receiving a preliminary non-binding ...

U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a preliminary non-binding acquisition offer. The company got an acquisition offer from Laurent Junique, its Founder, Executive Chairman, Director, and CEO, for a purchase price of $6.60/share or ADS in cash. The company has created a special committee of the Board, comprised solely of independent and disinterested directors, to consider the proposal letter dated Jan. 2, 2024. TDCX shares surged 28% to $6.18 on Wednesday. Here are some other big stocks recording gains in today’s session. Dyne Therapeutics, Inc. (NASDAQ: DYN) shares jumped 16.2% to $15.17. Dyne Therapeutics ...

Arrowhead Pharma (NASDAQ:ARWR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Arrowhead Pharma, revealing an average target of $38.25, a high estimate of $50.00, and a low estimate of $29.00. This current average reflects an increase of 10.87% from the previous average price target of $34.50. Diving into Analyst Ratings: An In-Depth Exploration The perception of Arrowhead Pharma by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jason Gerberry B of A Securities Raises Buy $37.00 $29.00 Jason Gerberry B of A Securities Announces Buy $29.00 - Michael Ulz Morgan Stanley Lowers Equal-Weight $37.00 $40.00 Luca Issi RBC Capital Maintains Outperform $50.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arrowhead Pharma. This offers insight ...Full story available on Benzinga.com